LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

10.54 -0.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.48

Max

10.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+108.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	453M 1.2B
Ankstesnė atidarymo kaina	10.92
Ankstesnė uždarymo kaina	10.54

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-27 23:53; UTC

Karštos akcijos

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

2026-02-27 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

2026-02-28 21:36; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 15:20; UTC

Uždarbis

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

2026-02-28 14:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 14:38; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

2026-02-28 13:47; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 13:44; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

2026-02-28 13:14; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

2026-02-28 02:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

2026-02-28 02:00; UTC

Įsigijimai, susijungimai, perėmimai

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

2026-02-28 02:00; UTC

Įsigijimai, susijungimai, perėmimai

Six Months, 9 Offers and $81 Billion. How -2-

2026-02-28 00:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

2026-02-27 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

2026-02-27 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

2026-02-27 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-27 21:30; UTC

Uždarbis

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

2026-02-27 21:30; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

2026-02-27 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

2026-02-27 21:17; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026-02-27 21:10; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

2026-02-27 21:09; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

2026-02-27 21:00; UTC

Uždarbis

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

2026-02-27 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

2026-02-27 20:24; UTC

Rinkos pokalbiai

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

2026-02-27 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

2026-02-27 20:12; UTC

Rinkos pokalbiai

Nike Seen With Further Challenges in China -- Market Talk

2026-02-27 19:44; UTC

Rinkos pokalbiai

Gold Caps Historic Month -- Market Talk

2026-02-27 19:39; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

108.87% į viršų

12 mėnesių prognozė

Vidutinis 22.14 USD 108.87%

Aukščiausias 30 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.